Pay in 4 interest-free payments of $6.21 Learn more
Ships within 48 hours · Estimated delivery Aug 26 - Aug 31
Wegovy is specifically designed to address overweight and obesity concerns and has been approved for people with a body mass index (BMI) of 30 or higher or a BMI of 27 or higher in combination with weight-related conditions like high blood pressure, diabetes, or high cholesterol
The FTC would have had more market evidence of competitive alternatives when it began its PBM investigation
Meier JJ, Gethmann A, Nauck MA et al (2006) The glucagon-like peptide-1 metabolite GLP-1-(936) amide reduces postprandial glycemia independently of gastric emptying and insulin secretion in humans
As these GLP-1 drugs become more prominent, balancing the evident public interest with concerns and ethical distribution will be pivotal in their narrative moving forward
6 months for the price of 4 advertised 6-month estimate: Varies by active promo Insurance: No Self-pay: Yes Clinical Features Lab testing: No Dietitian access: No Verified Pharmacy: FDA-regulated 503A compounding pharmacies
US$ 24.40
US$ 22.43
US$ 28.17
US$ 28.98
US$ 20.34
US$ 28.79
